The contribution of genetic factors to the age at onset in multiple sclerosis is poorly understood. Our objective was to investigate the disease modifying effects of HLA-DRB1 alleles and allele interactions on age at onset of multiple sclerosis. High-resolution four-digit HLA-DRB1 genotyping was performed in a cohort of 461 multiple sclerosis patients from the Perth Demyelinating Diseases Database. Carriage of the HLA-DRB1*1501 risk allele was not significantly associated with age at onset but HLA-DRB1*0801 was associated with a later onset of the disease. The HLA-DRB1*0401 allele was associated with a reduced age at onset when combined with DRB1*1501 but may delay age at onset when combined with DRB1*0801. These findings indicate that epistatic interactions at the HLA-DRB1 locus have significant modifying effects on age at onset of multiple sclerosis and demonstrate the value of high-resolution genotyping in detecting such associations.
Confavreux C. , Vukusic S.Age at disability milestones in multiple sclerosis . Brain2006; 129: 595-605.
2.
Ebers GCEnvironmental factors and multiple sclerosis. Lancet Neurol2008; 7: 268-277.
3.
Kurtzke JF, Page WF, Murphy FM, et al. Epidemiology of multiple sclerosis in US veterans. 4. Age at onset. Neuroepidemiology1992; 11: 226-235.
4.
Sadovnick AD , Yee IM, Guimond C., et al. Age of onset in concordant twins and other relative pairs with multiple sclerosis. Am J Epidemiol2009; 170: 289-296.
5.
Huang R., Hughes M., Mobley S., et al. APOE genotypes in African American female multiple sclerosis patients. Neurosci Lett2007; 414: 51-56.
6.
Dyment DA, Herrera BM, Cader MZ, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet2005; 14: 2019-2026.
7.
Lincoln MR, Montpetit A., Cader MZ, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet2005; 37: 1108-1112.
8.
Hafler DA, Compston A., Sawcer S., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med2007; 357: 851-862.
9.
DeLuca GC , Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA2007 ; 104: 20896-20901.
10.
Cree BA, Reich DE, Khan O., et al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol2009; 66: 226-233.
11.
Celius EG, Harbo HF, Egeland T., et al. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci2000; 178: 132-135.
12.
Masterman T. , Ligers A., Olsson T., et al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol2000; 48: 211-219.
13.
Hensiek AE, Sawcer SJ, Feakes R., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry2002; 72: 184-187.
14.
Ramagopalan SV, Byrnes JK, Dyment DA, et al. Parent-of-origin of HLA-DRB1*1501 and age of onset of multiple sclerosis. J Hum Genet2009; 54: 547-549.
15.
Al-Shammri S. , Nelson RF, Al-Muzairi I., et al. HLA determinants of susceptibility to multiple sclerosis in an Arabian Gulf population. Mult Scler2004; 10: 381-386. 16. Barcellos LF, Sawcer S., Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet2006; 15: 2813-2824.
16.
Poser CM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227-231.
17.
Compston A. , Edan G., Goodkin D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol2001; 50: 121-127.
18.
Welborn TAThe Besselton Study: mapping population health. Cardiovascular and respiratory disease risk factors in Busselton, Australia. Sydney: Australasian Medical Publishing Company, 1998.
Sayer D., Whidborne R., Brestovac B., et al. HLA-DRB1 DNA sequencing based typing: an approach suitable for high throughput typing including unrelated bone marrow registry donors. Tissue Antigens2001; 57: 46-54.
21.
Wu JS, Zhang MN, Carroll WM, et al. Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatry2008; 79: 1022-1026.
22.
Miller DH, Hornabrook RW, Purdie G.The natural history of multiple sclerosis: a regional study with some longitudinal data. J Neurol Neurosurg Psychiatry1992; 55: 341-346.
23.
Kremenchutzky M., Cottrell D., Rice G., et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain1999; 122: 1941-1950.
24.
Wu JS, Qiu W., Castley JP, et al. Frequency of HLA-DRB1 alleles and disease-modifying effects in a large West Australian multiple sclerosis cohort. J Neurology2009; 256: S158.
25.
Masterman T. , Hillert J.HLA-DR15 and age at onset in multiple sclerosis . Eur J Neurol2002; 9: 179-180.
26.
Kwon OJ, Karni A., Israel S., et al. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol1999; 56: 555-560.
27.
Svejgaard A.The immunogenetics of multiple sclerosis. Immunogenetics2008; 60: 275-286.
28.
Ramagopalan SV, McMahon R., Dyment DA, et al. An extension to a statistical approach for family based association studies provides insights into genetic risk factors for multiple sclerosis in the HLA-DRB1 gene. BMC Med Genet2009; 10: 10.
29.
Price P., Witt C., Allcock R., et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev1999; 167: 257-274.
30.
Steenkiste A., Valdes AM, Feolo M., et al. 14th International HLA and Immunogenetics Workshop: report on the HLA component of type 1 diabetes . Tissue Antigens2007; 69(Suppl): 214-225.
